European Archives - Page 97 of 1138 - European Medical Journal

Eli Lilly plans record $50bn US manufacturing investment

The company’s investment will expand its US manufacturing footprint and is the largest investment of its kind in history.

Copper Dysregulation Identified as Key Driver of Ageing

Increased copper activity contributes to ageing-related oxidative stress, but targeted chelation therapy may offer a promising intervention.

Teleneurorehabilitation: A Safe, Effective Alternative for Parkinson’s Treatment

Teleneurorehabilitation safely improves Parkinson’s symptoms and quality of life, offering a viable alternative to in-person therapy.

Cycling JAK Inhibitors More Effective Than Switching to Biologics in Rheumatoid Arthritis

New research suggests that cycling between JAK inhibitors may be more effective than switching to biologic DMARDs in rheumatoid arthritis patients who do not initially respond to JAKis.

ACL Injury Risk Lower in Women on Hormonal Contraceptives

Women using hormonal contraceptives have a lower incidence of ACL injuries requiring reconstruction than non-users, according to a large-scale study.

New Genetic Biomarkers and Treatments Identified for Sepsis Using AI

Machine learning identifies key genes and potential treatments for sepsis, improving diagnosis and offering new therapeutic targets.

Eytan Stein

Hema Now: Episode 11: Decoding Leukaemia's Epigenetic Drivers

Eytan Stein, Chief of the Leukaemia Service; Attending Physician, Memorial Sloan Kettering Cancer Center, New York, USA

Chiesi’s Enrico Piccinini on driving action for Rare Disease Day

Find out what the Senior Vice President, EU & International, Rare Diseases, Chiesi Group, thinks the pharma industry should consider on Rare Disease Day.

AI Model Predicts Stoma Risk After Crohn’s Disease Surgery

A machine learning model has been developed to predict the need for temporary stoma formation after intestinal resection in Crohn’s disease patients.

New Evidence Supports Tildrakizumab for Scalp Psoriasis

Patients initially receiving placebo experienced notable improvement after switching to tildrakizumab.